Invitation to Tender 2015/16 (updated)

1. Schedule 1 sets out the definitions used in this invitation;
2. Schedule 2 specifies the pharmaceuticals for which you may submit a Tender Bid in relation to community supply and/or hospital supply;
3. Schedule 3 describes the process PHARMAC intends to follow in relation to this tender, and provides instructions on how to submit a Tender Bid in relation to community supply and/or hospital supply;
4. Schedule 4 sets out terms that will apply if your Tender Bid in relation to community and/or hospital supply is awarded Sole Supply Status and/or Hospital Supply Status;
5. Schedule 5 sets out the additional terms that will apply if your Tender Bid in relation to community supply is awarded Sole Supply Status; and
6. Schedule 6 sets out the additional terms that will apply if your Tender Bid in relation to hospital supply is awarded Hospital Supply Status.

This invitation to tender also incorporates the information on the Electronic Portal referred to in this invitation.

If you wish to submit a Tender Bid in relation to community supply and/or hospital supply, you must submit it via the Electronic Portal to PHARMAC no later than 5pm (New Zealand time) on Thursday 17 December 2015.

If you have any inquiries about this invitation you should contact the Tender Analysts at tender@pharmac.govt.nz (Laurence Holding on +64 4 901 2844 or Katie Brownless on +64 4 916 7522).

We look forward to receiving your tender.

Clarification of Combined market and Split market for Lamivudine

Lamivudine (combined market) is where PHARMAC could award a tender to either a Tab 150 mg  presentation OR Tab 300 mg presentation. Should PHARMAC accept a bid under this scenario only one of the presentations would be listed for the duration of the Sole Supply Period.

Lamivudine (split market) is where PHARMAC could award a tender for both the Tab 150 mg presentation AND a tender for the Tab 300 mg presentation. Should PHARMAC accept a bid under this scenario, PHARMAC could also award a tender/enter into another agreement for the other presentation.

Clarification of Price change in the 2015/16 Invitation to Tender, Schedule 5, Clause 3.1

If a supplier provides a lead time of 1 month or less, this would result in a price change on the 12^th of the month prior to the Start Date immediately following the notification date.

Incumbent suppliers may implement a price change on the 1^st of the month, prior to the Start Date as per Clause 3.1(b) (ii), conditional upon having a minimum lead time of 2 months and that a supplier’s intention is stated in the tender bid for a pharmaceutical.

As stated in Clause 3.1 (b) (iii), if a supplier does not state in their tender bid which of the two options stated in Clauses 3.1 (b) (i) or (b) (ii) applies for a pharmaceutical, Clause (b) (i) will apply.

The “Lead Time Comments” section in the tender bid in the electronic portal would be the appropriate place to state which of the options in clause 3.1 (b) you wish to apply.

PHARMAC may, at its sole discretion, publish how any price changes for incumbents would occur as stated in Clause 3.1 (c) so that the supply chain, in particular wholesalers, can best manage stock levels and the impact of price changes.

Product Identification Codes

The introduction of CTPP codes was as the result of PHARMAC supporting the across government initiative to use the New Zealand Medicines Terminology (NZMT) Containered Trade Product Pack (CTPP) number. CTPP codes are freely available, and produced by the New Zealand Universal List of Medicines (NZULM). The NZULM has retrospectively produced codes for all items currently included in the Pharmaceutical Schedule and new codes for new products to be listed would be available upon request by suppliers at no charge. The NOPC would be the appropriate place to put these should you not have them available at the time of bidding.

Clarification of widening of access

Three chemicals have been included in the 2015/16 ITT with the option for suppliers to bid for current access and widened access. Below are clarifications for what widened access criteria PHARMAC is considering:

Montelukast [widened access]
PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access to open listing of montelukast capsules.

Progesterone [widened access]
PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access of progesterone capsules to include use in menopause hormone therapy.  

Risperidone [widened access]
PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access to open listing of risperidone orally-disintegrating tablets.   

Temozolomide [widened access]
PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access of temozolomide capsules to include use in unresectable, well-differentiated neuroendocrine tumours, or use as a treatment beyond six cycles for high grade gliomas, or for both.  See Application Tracker for further details: https://connect.pharmac.govt.nz/apptracker/s/global-search/Temozolomide(external link)

Please note that suppliers are able to submit more than one bid per line item, stating the access criteria each bid would apply for.